Rutgers Professor Suzie Chen has found that riluzole, a U.S. Food and Drug Administration (FDA) approved drug used to treat Lou Gehrig’s disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.
A Phase 0 (zero) clinical trial of riluzole (brand name Rilutek), conducted by James Goydos, a surgical oncologist with The Cancer Institute of New Jersey (CINJ), is in process with a small group of late-stage (stage 3 or 4) melanoma patients. Phase 0 is a recent designation by the FDA for exploratory, first-in-human trials. Goydos reported preliminary but encouraging findings from the trial during a plenary session today at the annual meeting of the American Association for Cancer Research in San Diego.
In about 70 percent of melanoma cases, the disease appears in places that are exposed to the sun. It can then spread to other parts of the body and may become lethal. This type of cancer is not generally responsive to chemotherapy. According to a report from the National Cancer Institute, the incidence rate of melanoma has more than doubled in the past 20 years in the United States.
Chen had reported in 2003 the discovery of a gene – Grm1 – responsible for melanoma in laboratory mice. Its normal functions are in the brain, where it is associated with learning and memory; but when this gene is expressed or turned on in certain skin cells, it leads to the development of melanoma.
A common feature to both ALS and melanoma cells is excess glutamate, a cellular growth factor or food for cells. An excess of this protein can overstimulate neurons to the point where they burn out – a possible explanation of what happens in ALS.
In a melanoma cell, the glutamate enters a pernicious loop where it binds to the malfunctioning cell surface protein. The protein operates as a receptor, stimulating the cell to produce more glutamate that, in turn, binds to the receptor, stimulating more production. This cellular “overfeeding” results in the growth and expansion of the melanoma.
“We fixed on riluzole because it is a known inhibitor of glutamate release, the suspected culprit in ALS and possibly melanoma,” said Chen, a professor of chemical biology at the Susan Lehman Cullen Laboratory of Cancer Research in the Ernest Mario School of Pharmacy of Rutgers, The State University of New Jersey, and a CINJ member. “While most of our studies five years ago were with animals, it is humans that we are really interested in.”
In new laboratory experiments using cultures of human melanoma cell lines, riluzole appeared to shut off the glutamate, thus slowing the growth rate of the melanoma cells. Moving forward with animal studies, riluzole demonstrated the same suppression of tumor cell growth and progression seen in cultured cells.
Building on this foundation, Chen joined Goydos to pursue human clinical trials. Goydos is a surgical oncologist and director of the Melanoma and Soft Tissue Oncology Unit at the Cancer Institute of New Jersey, part of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School (UMDNJ-RWJMS). Goydos is also an Associate Professor of surgery at UMDNJ-RWJMS.
A grant from the National Cancer Institute enabled Goydos to begin an initial or Phase 0 trial. The use of late-stage patients is a requirement. It is a purely experimental exercise designed to make sure the drug that appeared to work in pre-clinical trials is actually performing as expected in humans – “to see if you are hitting your targets,” as Goydos phrased it.
Goydos and his colleagues recruited 11 patients to whom riluzole was administered for two weeks. The researchers tracked the patients’ progress before and after the treatment with biopsies and PET scans, a form of nuclear medicine imaging typically used to detect cancer. “Our preliminary results show three solid positive responses in nine of the patients who had been able to complete the trial to date,” Goydos said. “It is actually quite amazing that we got as many as we did.”
Goydos also noted that there were other patients in the group who showed some indications of responding to riluzole and they will be reassessed when the trial is completed.
“In this situation we hit our target in at least in three, possibly four or five patients,” Goydos said. “It provides enough data to show that we should go on to a more extensive trial.”
The next step is a combined Phase 1/2 trial. Phase 1 will be a toxicity trial where the dosage is increased gradually to determine the appropriate dose and identify possible toxic side-effects.
“We will administer riluzole to the first five or six patients, look for toxicity and then move on to Phase 2,” Goydos said. “We can do this in one combined trial since we are dealing with an FDA-approved drug and not an experimental drug that has never been given to people before.”
Goydos said that the Phase 1/2 trial should begin in August, and he anticipates that it will include between 50 and 100 patients with stage 4 melanoma.
“I think this drug is going to be extremely important as an adjunct to surgical treatment of stage 3 or stage 4 melanoma,” Goydos said. “The challenge is to keep it from recurring, which has happened in patients on the order of 50 percent. With low toxicity likely, riluzole could potentially be given for long periods of time to slow down the metabolic processes responsible for the disease’s recurrence.”
Joseph Blumberg | EurekAlert!
The dense vessel network regulates formation of thrombocytes in the bone marrow
25.07.2017 | Rudolf-Virchow-Zentrum für Experimentelle Biomedizin der Universität Würzburg
Fungi that evolved to eat wood offer new biomass conversion tool
25.07.2017 | University of Massachusetts at Amherst
21.07.2017 | Event News
19.07.2017 | Event News
12.07.2017 | Event News
25.07.2017 | Physics and Astronomy
25.07.2017 | Earth Sciences
25.07.2017 | Life Sciences